Cradle
-19%
est. 2Y upside i
Leverage AI to generate protein candidates and improve their properties. More breakthroughs in fewer experiments — guided by your own experimental data.
Rank
#3301
Sector
Biotech / TechBio / AI SaaS
Est. Liquidity
~3Y
Data Quality
Data: LowGiven missing valuation data, analysis confidence is low.
Last updated: July 3, 2026
If Cradle achieves category leadership and an IPO window opens, forward multiple could hold at 25x, yielding 66% upside after 20% dilution.
Multiple converges to 15x, but dilution and preference stack limit upside to near zero.
Multiple compresses to 8x due to big tech competition, and preference stack erodes common value, resulting in -56% return after dilution.
Preference Stack Risk
highFunding Intensity
26%Total funding of $102.5M represents 25.6% of estimated entry valuation, creating significant preference overhang.
Dilution Risk
highWith $102.5M raised and no profitability, further funding likely within 2 years, diluting existing holders by ~20%.
Secondary Liquidity
noneNo secondary market activity observed.
Questions to Ask at the Interview
Strategic questions based on Cradle's data — designed to show you've done your homework.
- 1
“How does Cradle's lab-in-the-loop moat compare to Generative AI models from big tech?”
- 2
“What is the company's cash runway and expected time to next fundraise?”
- 3
“How does the preference stack affect common stock value in an acquisition scenario?”
Community
Valuation Sentiment
Our model estimates -19% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.